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Abstract
Background: Experimental screening of large sets of peptides with respect to their MHC binding capabilities is still
very demanding due to the large number of possible peptide sequences and the extensive polymorphism of the
MHC proteins. Therefore, there is significant interest in the development of computational methods for predicting
the binding capability of peptides to MHC molecules, as a first step towards selecting peptides for actual
screening.
Results: We have examined the performance of four diverse MHC Class I prediction methods on comparatively
large HLA-A and HLA-B allele peptide binding datasets extracted from the Immune Epitope Database and Analysis
resource (IEDB). The chosen methods span a representative cross-section of available methodology for MHC
binding predictions. Until the development of IEDB, such an analysis was not possible, as the available peptide
sequence datasets were small and spread out over many separate efforts. We tested three datasets which differ in
the IC50 cutoff criteria used to select the binders and non-binders. The best performance was achieved when
predictions were performed on the dataset consisting only of strong binders (IC50 less than 10 nM) and clear non-
binders (IC50 greater than 10,000 nM). In addition, robustness of the predictions was only achieved for alleles that
were represented with a sufficiently large (greater than 200), balanced set of binders and non-binders.
Conclusions: All four methods show good to excellent performance on the comprehensive datasets, with the
artificial neural networks based method outperforming the other methods. However, all methods show
pronounced difficulties in correctly categorizing intermediate binders.
Background
A precise understanding of host immune responses is
crucial for basic immunological studies as well as for
designing effective disease prevention strategies. Epi-
tope-based analysis methods are effective approaches at
assessing immune response, allowing for the quantifica-
tion of the interaction between a host and pathogen, of
vaccine effectiveness or other prevention strategies.
As part of the adaptive immune response, antigens are
recognized by two different types of receptor molecules:
immunoglobulins which act as antigen receptors on B
cells and antigen-specific T-cell receptors (TCRs) [1,2].
The latter receptor molecules recognize antigens which
are displayed on the surface of cells. These antigens are
peptide fragments derived from intracellular pathogens
such as viruses or bacteria, or alternatively pathogens
which have been endocytosed by the cells. The cytosolic
degradation of pathogen proteins is carried out by a large,
multicatalytic protease complex, the proteasome. Subse-
quently, the protein fragments are transported into the
endoplasmic reticulum via the transporters associated
with antigen processing (TAP), prior to being loaded onto
the major histocompatibility complex (MHC) molecules,
which are specialized host-cell glycoproteins that form a
complex with the peptidic fragments. These fragments are
then translocated to the cell surface as part of the MHC-
peptide complex for TCR recognition. Peptides which trig-
ger an immune response by this process are called T-cell
epitopes. An alternative processing pathway is provided by
the signal peptidase which bypasses the proteosome and
TAP transport. The signal peptidase cleaves signal pep-
tides from proteins entering the endoplasmic reticulum,
which are then bound to MHC class I molecules. Particu-
larly HLA-A*02 molecules, which prefer hydrophobic
sequences, acquire peptides in this manner [3].
MHC class I molecules deliver peptides from the cyto-
sol and are recognized by CD8+ T cells. The binding of
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antigenic peptides from pathogens to MHC class I
molecules is one of the crucial steps in the immunologi-
cal response against an infectious pathogen [2]. While
not all peptides that bind MHC molecules become epi-
topes, all T-cell epitopes need to bind to MHC mole-
cules. Therefore, deciphering why certain peptides
become epitopes and others do not is central to the
development of a precise understanding of host immune
responses.
The Immune Epitope Database and Analysis Resource
(IEDB) [4,5] is a central data repository and service,
containing MHC binding data relating to B cell and T
cell epitopes from infectious pathogens, experimental
pathogens and self-antigens (autoantigens). In most
cases, T cell epitopes are defined as peptides that are
not only presented to T-cell receptors on the cell sur-
face by specific MHC molecules, but that also trigger an
immune response. IEDB encompasses patent data from
biotechnological and pharmaceutical companies, as well
as direct submissions from research programs and part-
ners. Within the database, epitopes are linked with
objective and quantifiable measurements with regard to
their binding affinity to specific, well defined immune
system receptors.
IEDB is not the first database to store such informa-
tion, as there are a number of databases which include
similar information. However, although most of the com-
ponents of IEDB can be found in other resources, none
contains them all. For example, SYFPEITHI [6] contains
carefully mapped epitopes or naturally processed pep-
tides, but unlikely IEDB, does not annotate the context in
which they are immunogenic. The Los Alamos HIV
Molecular Immunology Database [7], focuses on a
restricted dataset. FIMM [8], is of modest size and solely
focuses on cellular immunology and MHCPEP [9], while
still widely used, has not been updated since 1998. While
MHCBN [10] and AntiJen [11,12] contain peptide entries
that are not contained in IEDB, IEDB has more entries
than any other existing database in this field.
While IEDB is the first epitope database of significant
size, the experimental screening of large sets of peptides
with respect to their MHC binding capabilities is still
very demanding due to the large number of possible
peptide sequences and the extensive polymorphism of
the MHC proteins. Therefore, there is significant inter-
est in the development of computational methods for
predicting the binding capability of peptides to MHC
molecules, as a first step towards selecting peptides for
actual screening.
Sequence- and structure-based methods, as well as
combinations thereof, have been developed and were
used for both classification and regression. Classification
models aim to distinguish binding from non-binding
peptides, whereas regression methods attempt to predict
the binding affinity of peptides to MHC molecules. As
the quantity of publicly available binding data has been
limited until recently, most methods focus on classifica-
tion. A review of previous methods can be found in
Tong et al. [13].
Sequence-based methods are computationally more
efficient than structure-based methods. However, they
are hampered by the need for sufficient experimental
data and therefore only achieve high performance on
already intensively investigated MHC alleles. Addition-
ally, sequence-based methods do not provide a structural
interpretation of their results, which is of importance for
designing peptidic vaccines and drug-like molecules.
Structure-based methods have the advantage of being
independent of the amount of available experimental
binding data, but are computationally intensive and
therefore not suited for the screening of large datasets.
A recent approach [14] performs a combined struc-
ture-sequence-based prediction by incorporating struc-
tural information obtained from molecular modeling
into a sequence-based prediction model. This method
therefore not only allows for the fast prediction of MHC
class I binders, but also for the efficient construction of
docked peptide conformations. This approach is the
only prediction method available today, which also
allows for the construction of such conformations. We
have evaluated this approach for MHC class I alleles of
the human leukocyte antigen (HLA) genes A and B for
which extensive datasets were available in IEDB and
compared it to two sequence-based prediction methods
from the literature. These two sequence-based predic-
tion methods are the same as examined in Antes et al.
[14] and were chosen here as well for comparison rea-
sons. In addition, we have evaluated the prediction ser-
ver NetMHC which has shown to be among the best
predictors in recent comparison tests [15].
A major focus of this study is on testing the depen-
dency in performance of well established methods on
the use of different training and testing datasets. The
four methods we have chosen span a representative
cross section of available methodology for MHC-peptide
binding predictions, from simple binary (SVMHC) to
rather sophisticated encoding (DynaPredPOS). The cho-
sen methods include advanced learning strategies such
as support vector machines (SVM) (DynaPredPOS and
SVMHC) and artificial neural networks (ANN)
(NetMHC), as well as the more straightforward quantita-
tive matrix based prediction (YKW).
Lin et al [15] performed a comparative evaluation of
thirty prediction servers developed by 19 groups using
an independent dataset. Each server was accessed via
the Internet and the predictions were recorded, normal-
ized, and compared. Peters et al [16] performed an
extensive analysis of predictors, in which they trained
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and tested their in-house methods, but did not reimple-
ment any of the external methods used. Instead, web
interfaces were used for the external methods. Zhang
et al [17] evaluated five prediction methods using public
web interfaces with the default parameters of the meth-
ods in question. Three of these methods were in-house
and two were external. The authors discarded all pep-
tides used for training their own methods for subse-
quent testing, but there was some concern that there
was some overlap between evaluation and training data
sets for one of the external methods. They also trained
their own predictors on a dataset of binders and non-
binders for a wide variety of alleles, testing on a second
set of binders and non-binders which were released at a
later point in time. The goal of this analysis was to
examine the performance of these predictors on alleles
for which little or no data was available (which were
described as pan-specific predictors). The alleles for
which such pan-specific analyses were performed were
not identified and only limited information on the meth-
ods performance was available.
Work by other groups which preceded the study by
Zhang et al [17], included a support vector machine
based approach [18], which was trained and tested on a
relatively small datasets, where different predictive mod-
els are estimated for different alleles, using training data
from ‘similar’ alleles. The notion of allele similarity is
defined by the user therefore requiring human interven-
tion which is not a systematic procedure. A binding
energy model [19], which was trained and tested on
very small datasets, was used to make pan-specific pre-
dictions for only two alleles. A further study [20], which
utilized hidden Markov models and artificial neural net-
works as predictive engines, was again trained on rela-
tively small datasets. The system was used to identify
so-called promiscuous peptides, which bind well to a
number of diverse alleles.
In this study, we reimplemented the external methods
YKW and SVMHC and trained and tested them along
side our in-house method DynaPredPOS on a wide vari-
ety of datasets. This allows for a more objective compar-
ison of the performance of these methods. We also
tested NetMHC in all the tests where training was not
necessary; this server is only available via a web interface
and thus could not be reimplemented for this study. In
contrast to the previous work described, we perform a
detailed analysis of the performance of predictors
trained on one allele and their ability to accurately pre-
dict other alleles.
Methods
Datasets with Complete Peptides
In this section we describe the datasets we use that con-
tain data incorporating full peptides, i.e. information on
all nine residues. IEDB was mined for allele/peptide
data on May 16th, 2007. Only alleles with a significant
number of 9-mer binding and non-binding peptides
(the total number being greater than 200) where
included in the analysis (Table 1). The data was
imported into a local relational database to allow for
efficient analysis.
Three datasets were generated for each allele: all pep-
tides available in IEDB (the full dataset or Dataset F), all
peptides with an available quantitative laboratory test
result (IC50 or in rare cases EC50), but including only
those with a binding affinity between 50 nM and 1000
nM, i.e. including only weak binders and non-binders
(the intermediate dataset or Dataset I) and all peptides
with an IC50, but excluding those with a binding affinity
between 10 nM and 10,000 nM, i.e. including only very
strong binders and very clear non-binders (the strong
dataset or Dataset S). Alleles with less than 200 peptides
in total (binders and non-binders) were excluded from
the analysis in all datasets. IC50 measures the half maxi-
mal (50%) inhibitory concentration (IC) of a radioactive
isotope labeled standard peptide to MHC molecules,
whereas EC50 measures the half maximal effective con-
centration (EC) of such a reference peptide [4,5]. For
Dataset F, in cases where a peptide with a particular
sequence had more than one entry in IEDB for a particu-
lar allele (for example the peptide was tested with same
allele by two different laboratories, resulting in two sepa-
rate IEDB entries), this peptide was included only once. If
no binding constant was available, the peptide was also
only included once in Dataset F. If a peptide was
described as a binder by one laboratory and a non-binder
by another laboratory, it was included both as a binder
and non-binder in Dataset F. For Datasets I and S, in
cases where peptide-allele complexes had duplicate
entries in IEDB and the binding affinities differed, result-
ing in at least one entry with a binding affinity which fell
within the ranges used in Datasets I and S, this peptide
was included in the respective dataset. If, for a particular
allele, there was more than one binding affinity measure-
ment made that fell into one of the ranges used in the
analysis, an average binding affinity was calculated and
used for that peptide in that particular range. Any pep-
tides annotated in IEDB as binders with IC50 values
greater than 500 nM, and peptides annotated as non-bin-
ders with IC50 values less than 500 nM were discarded.
We have made the three datasets available: http://www.
mpi-inf.mpg.de/~roomp/benchmarks/list.htm.
We also tested an independent dataset recently pub-
lished by Lin et al [15], derived from the tumor antigen
survivin and the cytomegalovirus internal matrix protein
pp65. This data was not used for training any of the
four prediction methods in this study and therefore
serves as an independent test set.
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Prediction Methods
Four prediction methods were evaluated with respect to
their ability to correctly classify binders and non-binders
in the datasets described above. As already described in
the introduction, the chosen methods span a representa-
tive cross-section of available methodology for MHC
binding predictions.
The first prediction method used (DynaPredPOS) was
developed in our laboratory [14]. The general strategy
followed to generate this prediction model, involves as a
first step molecular dynamics simulations from which
energetic information for all 20 amino acids in each of
the nine binding pockets of the binding groove of HLA-
A*0201 was extracted. The algorithm is based on the
assumption that the total binding affinity of a peptide can
be approximated by the sum of the binding affinities of
its individual amino acids, neglecting the effect of inter-
actions between neighboring residues. Therefore, each
amino acid was simulated individually in each binding
pocket; initial conformations were constructed from
available crystal structures and, in order to stabilize the
peptide conformations, the single so-called pivot amino
acid was extended by a glycine residue on both sides (for
terminating residues on the non-terminating side only)
resulting in pseudo-dimers or -trimers which were used
in the simulations. For amino acids with no available
experimental structures, existing residues were mutated
to the corresponding amino acid using the program
SCWRL3 [21]. Subsequently, a binding-free-energy-based
scoring matrix (BFESM) was constructed which included
important energy terms reflecting the binding properties
of the amino acids derived from the simulations. Each
entry in the matrix represented one feature (energy term)
of a particular amino acid in a particular binding pocket.
The BFESM is used to generate a feature vector for
each given peptide in the training dataset; all vectors
together produce a feature matrix for model generation
and prediction. A local feature matrix is constructed
from the BFESM which uses all residue and binding
pocket positional information from the scoring matrix.
This matrix provides a basis for logistic regression and
SVM training [22] of the final model (DynaPredPOS).
Table 1 Prediction accuracies for the full dataset
Allele Name Binders Non-Binders Total DynaPredPOS NetMHC SVMHC YKW
(n) (n) (n) AUC AUC AUC AUC
1 A*0101 163 1316 1479 0.93 0.98 0.95 0.94
2 A*0201 1544 1929 3473 0.93 0.96 0.92 0.91
3 A*0202 723 697 1420 0.88 0.93 0.85 0.85
4 A*0203 732 685 1417 0.88 0.95 0.86 0.84
5 A*0206 633 782 1415 0.88 0.95 0.87 0.86
6 A*0301 637 1618 2255 0.89 0.96 0.88 0.80
7 A*1101 816 1279 2095 0.92 0.96 0.90 0.91
8 A*2402 202 464 666 0.80 0.85 0.78 0.81
9 A*2601 69 885 954 0.84 0.93 0.83 0.84
10 A*3101 510 1480 1990 0.89 0.95 0.89 0.88
11 A*3301 203 994 1197 0.88 0.96 0.89 0.88
12 A*6801 578 620 1198 0.85 0.92 0.82 0.81
13 A*6802 439 980 1419 0.84 0.93 0.85 0.83
14 B*0702 238 1110 1348 0.94 0.98 0.94 0.93
15 B*0801 23 687 710 0.82 0.99 0.78 0.79
16 B*1501 182 836 1018 0.86 0.97 0.89 0.90
17 B*2705 81 917 998 0.93 0.97 0.90 0.94
18 B*3501 273 578 851 0.83 0.93 0.84 0.85
19 B*4001 94 1112 1206 0.90 0.97 0.93 0.91
20 B*4402 76 136 212 0.77 0.84 0.75 0.76
21 B*4403 71 142 213 0.68 0.81 0.65 0.70
22 B*5101 108 249 357 0.82 0.93 0.80 0.81
23 B*5301 127 228 355 0.86 0.95 0.85 0.87
24 B*5801 78 893 971 0.90 0.99 0.93 0.93
Average AUC 0.86 0.94 0.86 0.86
Alleles included in the study with the number of binders and non-binders available; all available binders and non-binders were included in the analysis
irrespective of whether quantitative laboratory test data was available or not (Dataset F). Only unique peptide sequences were included in the counts; all
peptides with more than one entry for a particular allele in IEDB were counted once only. The overall performance of the four prediction models on different
alleles is shown; AUC = area under the curve (ROC analysis). The average AUC for each method is included at the bottom of each column.
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One feature unique to DynaPredPOS is the ability to
construct bound peptide conformations for all predicted
sequences. The bound conformations are generated by
connecting the saved residue conformations for the
simulation runs and performing a short energy minimi-
zation. In a detailed analysis [14], the constructed pep-
tide structures were refined within seconds to structures
with an average backbone RMSD of 1.53 Å from the
corresponding experimental structure.
Additionally, we evaluated two sequence-based predic-
tion methods from the literature. The first method is
SVMHC from Dönnes et al. [23], which is based on
SVMs and was implemented using the software package
SVM-LIGHT [24]. For this method, SVM kernels and
trade offs were optimized by systematic variation of the
parameters and evaluation of prediction performance
was made using Matthews Correlation coefficients [25],
which were used as the main measure of performance
for parameter optimization. The second sequence-based
prediction method we evaluated is YKW from Yu et al.
[26], which is based on data-derived matrices. The
matrix is generated using logarithmized propensities for
occurrence in binding vs. nonbinding peptides of amino
acids at specific positions within the peptide training set
to generate an initial matrix. The final matrix was
derived by a position dependent weighting of the initial
matrix which was derived by an analysis of binding data.
The SVMHC and YKW methods were re-implemented
for this study using the methodology reported in the
original publications.
The fourth and final method we evaluated is an artifi-
cial neural network based approach [27,28], which was
developed using ANN which are capable of performing
sensitive, quantitative predictions. Such quantitative
ANN were shown to be superior to conventional classi-
fication ANNs which have been trained to predict bind-
ing versus non-binding peptides. NetMHC has recently
been shown to be among the best predictors in an
extensive comparison of prediction servers whose per-
formance was evaluated with 176 peptides derived from
the tumor antigen survivin and the cytomegalovirus
internal matrix protein pp65 [15]. NetMHC is available
via http://www.cbs.dtu.dk/services/NetMHC/. NetMHC
could not be trained for this study as it was only acces-
sible via with web interface, and was therefore used for
testing purposes only. Also, it is probable, that at least
some of the data used to train the NetMHC server was
the same data which was retrieved from IEDB for this
study.
For Datasets F, I and S, training and testing of the
prediction models for SVMHC, YKW, and DynaPredPOS
was performed for each HLA-A and HLA-B allele sepa-
rately. In the case of DynaPredPOS, the same BFESM
generated from the molecular simulations on A*0201
was used to generate each new feature matrix for each
allele separately. For NetMHC, the peptide sequences
from Dataset F, I and S were submitted to the predic-
tion server and the prediction results were recorded.
The accuracy of the methods was assessed by generat-
ing areas under the curve (AUC, see ROC analysis [29]),
which is a widely used non-parametric performance
measure. ROC analysis tests the ability of models to
separate binders from non-binders without the need of
selecting a threshold. The values AUC ≥ 0.90 indicate
excellent, 0.90 > AUC ≥ 0.80 good, 0.80 > AUC ≥ 0.70
marginal and 0.70 > AUC poor predictions [30].
We used 10-fold cross validation to assess the accu-
racy of the predictions.
Robustness
In order to determine how dependent the reproducibil-
ity of the results of the prediction methods YKW,
SVMHC and DynaPredPOS are on the size of the avail-
able allele datasets (a phenomenon that we call robust-
ness), we tested the methods’ performance with
randomly selected balanced datasets of different sizes,
selected from all peptides available in IEDB for a parti-
cular allele (Dataset F). NetMHC was not included in
this analysis, because we were unable to retrain the sta-
tistical model.
The alleles examined were A*0201, A*3101 and
B*0702. The training was performed on each allele sepa-
rately, followed by testing using 10-fold cross validation.
The smallest balanced dataset for each allele consisted
of 50 randomly selected binders and 50 randomly
selected non-binders and the size of the largest dataset
depended on the overall number of binders or non-bin-
ders available for the allele. All prediction methods were
run on four randomly selected balanced datasets in each
size category for each allele.
Generalizability
By this test, we assess the ability of the statistical models
(YKW, SVMHC and DynaPredPOS), trained for the allele
A*0201, to generalize to other alleles. NetMHC was
again not included in this analysis, because we were
unable to retrain the statistical model. Training was per-
formed on Dataset F of A*0201, followed by testing on
Datasets F of all other alleles. This generalization ability
is essential for epitope prediction models as there are
many alleles with insufficient data for training an allele-
specific model.
Results and Discussion
Datasets with Complete Peptides
In this section we examine the dependency of the per-
formance of the four prediction methods on the selec-
tion criteria of the used training dataset.
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If all available peptides for an allele are used for the
prediction (Table 1, Dataset F), NetMHC performs parti-
cularly well, achieving the highest AUC for all 24 alleles
examined. All four methods had a predictive perfor-
mance of good or excellent for 20 or more of the 24
alleles. NetMHC significantly outperforms the three
other methods (Wilcoxon Rank Sum Test, P-value <
0.001) and no statistically significant difference between
the other three methods could be detected. Therefore,
the ranking of the methods can be described as
NetMHC > (DynaPredPOS, SVMHC, YKW).
The results are dependent on the size of the datasets:
for good results (AUC greater than 0.85), an allele’s
dataset generally has to contain more than 100 binders
and more than 100 non-binders (preferably more than
200 binders and more than 200 non-binders). Also,
datasets for which the number of binders and non-bin-
ders are relatively balanced produced larger AUCs (i.e.
better performance). Unbalanced datasets in IEDB gen-
erally have a substantially lower number of binders than
non-binders. For YKW, SVMHC and DynaPredPOS bet-
ter results were achieved for HLA-A than HLA-B. This
probably is due to the lower number of epitopes which
are available for HLA-B in IEDB and, in the case of
DynaPredPOS, due to the fact that the BFESM was gen-
erated using HLA-A*0201 simulation results. NetMHC
however achieved comparable results for both HLA-A
than HLA-B.
Intermediate binders (Table 2, Dataset I) were difficult
to classify. NetMHC had the best performance for 10 out
of 11 alleles. However, all methods showed at best mar-
ginal prediction performance (the largest achieved AUC
was 0.79) and in most cases the predictions were poor.
Restricting the datasets to peptides which were either
very strong binders or clear non-binders substantially
improved the results in most cases (Table 3, Dataset S);
with thirteen of fourteen alleles the best method,
NetMHC, achieved AUC equal to or greater than 0.99.
With the exception of allele A*2402, all methods had an
excellent predictive performance (AUC greater than
0.90). Despite a substantially lower number of data
points in Dataset S, a higher accuracy was found for the
best method for all alleles when compared with the
Datasets F. A typical ROC plot comparing the perfor-
mance of the four prediction methods for Dataset S is
shown in Figure 1.
Overall, the best performance was achieved in cases
where Dataset S was used, the number of binders in the
dataset was large (more than 200 binders and more
than 200 non-binders), the dataset was relatively well
balanced, the NetMHC method was used, and the allele
was of the HLA-A*02 type.
For the independent dataset of 176 peptides (Table 4),
while NetMHC was the best method for five of the
seven alleles tested there was no significant difference in
the performance of the methods. For all alleles, with the
exception of A*1101, at least one method had excellent
predictive performance (AUC greater than 0.90); gener-
ally at least two methods showed excellent predictive
performance.
Robustness
In this test we examined the dependency of the quality
of the obtained prediction models (YKW, SVMHC and
DynaPredPOS) on the size of the training sets used.
NetMHC was not included in this analysis as the predic-
tor is only available online and therefore could not be
trained by the authors. We found that in most cases the
AUCs stabilized at or close to their maximum level,
when the size of the randomly selected balanced dataset
Table 2 Prediction accuracies for the dataset containing only weak binders and non-binders
Allele Name Binders Non-Binders Total DynaPredPOS NetMHC SVMHC YKW
(n) (n) (n) AUC AUC AUC AUC
1 A*0201 616 135 751 0.67 0.77 0.65 0.66
2 A*0202 286 87 373 0.53 0.70 0.41 0.54
3 A*0203 261 126 387 0.58 0.79 0.58 0.60
4 A*0206 264 74 338 0.56 0.73 0.57 0.57
5 A*0301 335 106 441 0.58 0.70 0.60 0.59
6 A*1101 374 91 465 0.56 0.69 0.62 0.63
7 A*3101 278 103 381 0.42 0.69 0.48 0.56
8 A*3301 129 72 201 0.62 0.52 0.39 0.63
9 A*6801 273 96 369 0.54 0.68 0.44 0.57
10 A*6802 227 123 350 0.52 0.74 0.50 0.50
11 B*1501 169 33 202 0.59 0.79 0.49 0.59
Average AUC 0.56 0.71 0.52 0.59
Results from Dataset I, in which only weak binders (50 nM to 500 nM binding affinity) and non-binders (500 nM to 1000 nM binding affinity) were included.
Alleles included in Dataset F, which had fewer than 200 binders and non-binders in total in Dataset I, were no longer included in the analysis. The average AUC
for each method is included at the bottom of each column.
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consisted of more than 200 binders and 200 non-bin-
ders (Figure 2). This effect was observed with all three
prediction methods and for all three alleles included in
the study. SVMHC performance was less stable for small
datasets, which might be due to its simple encoding
method and is a significant drawback of this method.
Generalizability
Last, we evaluated the generalizability of YKW, SVMHC
and DynaPredPOS on all HLA-A and HLA-B alleles for
Datasets F. NetMHC was again not included in this test
because the model could not be trained by the authors.
In Figure 3 the AUCs for the models trained on the
A*0201 dataset is given for different alleles. It can be
seen that DynaPredPOS outperforms the other models
for alleles of the HLA-A*02 type, but for the other
alleles the performance of the three methods is very
similar. The prediction capabilities are good to marginal
for some alleles implying that cross-allele prediction is
feasible in some cases.
The MHC supertype classifications schemes generate
clustered sets of molecules with largely overlapping
Table 3 Prediction accuracies for the dataset containing only strong binders and clear non-binders
Allele Name Binders Non-Binders Total DynaPredPOS NetMHC SVMHC YKW
(n) (n) (n) AUC AUC AUC AUC
1 A*0101 34 284 318 0.96 1.00 0.96 0.97
2 A*0201 549 503 1052 0.97 0.99 0.97 0.95
3 A*0202 290 267 557 0.98 1.00 0.97 0.97
4 A*0203 273 255 528 0.97 0.99 0.96 0.96
5 A*0206 216 371 587 0.97 0.99 0.96 0.95
6 A*0301 123 332 455 0.93 1.00 0.94 0.95
7 A*1101 228 269 497 0.95 1.00 0.94 0.97
8 A*2402 69 272 341 0.88 0.84 0.84 0.85
9 A*2601 15 256 271 0.97 1.00 0.94 0.97
10 A*3101 114 349 463 0.96 1.00 0.96 0.97
11 A*3301 36 620 656 0.95 1.00 0.94 0.93
12 A*6801 155 235 390 0.95 1.00 0.94 0.94
13 A*6802 95 440 535 0.96 1.00 0.97 0.94
14 B*0702 45 161 206 0.95 1.00 0.96 0.93
Average AUC 0.95 0.99 0.95 0.95
Results from Dataset S, in which only strong binders (less than 10 nM binding affinity) and very clear non-binders (greater than 10,000 nM binding affinity) were
included. Alleles included in Dataset F, which had fewer than 200 binders and non-binders in total in Dataset S, were no longer included in the analysis. The
average AUC for each method is included at the bottom of each column.
Figure 1 Overall performance evaluation. ROC plot for the overall performance evaluation of SVMHC, YKW, DynaPredPOS with models that are
trained and tested on Dataset S pertaining to allele A*0201. NetMHC was only available online and therefore could not be trained; the results
shown result from testing with Dataset S.
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Table 4 Prediction accuracies for an independent dataset
Allele Binders Non-Binders Total DynaPredPOS NetMHC SVMHC YKW
(n) (n) (n) AUC AUC AUC AUC
1 A*0201 33 143 176 0.92 0.94 0.82 0.93
2 A*0301 11 165 176 0.77 0.92 0.70 0.85
3 A*1101 17 159 176 0.84 0.89 0.72 0.83
4 A*2402 37 139 176 0.90 0.78 0.90 0.64
5 B*0702 9 167 176 0.86 0.98 0.72 0.68
6 B*0801 10 166 176 0.97 0.92 0.97 0.61
7 B*1501 14 162 176 0.71 0.92 0.71 0.80
Average AUC 0.85 0.90 0.79 0.76
A set of 176 novel peptides, generated and tested by Lin et al [15], were used to test the prediction accuracy of the four methods in this study. The average
AUC for each method is included at the bottom of each column.
Figure 2 Robustness analysis. The reproducibility of the results of the prediction methods and their dependence on the size of the available
dataset was examined in selected alleles. Box plots of randomly selected balanced sets of binders and non-binders from Dataset F for the alleles
A*0201, A*3101, and B*0702 are shown. The smallest dataset for each allele consisted of 50 binders and 50 non-binders. The size of the largest
dataset for each allele depends on the total number of binders or non-binders available for that particular allele. NetMHC was not included in
this analysis as the predictor is only available online and could therefore not be trained by the authors.
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peptide repertoires [31,32]. These classification schemes
generally depend on features such as published motifs,
binding data and the analysis of shared repertoires of
binding peptides, etc. There has been interest in the
development of pan-specific algorithms that can predict
peptide binding to alleles for which limited or even no
experimental data is available. This would, in contrast to
the typical supertype classification scheme which
depends on the availability to such data, allow for the
prediction of binding in cases where no such data is
available.
In recent work by Zhang et al. [17], their predictor
was trained on a dataset of binders and non-binders for
a wide variety of alleles, and tested on a second set of
datasets which consisted of binders and non-binders
which were released at later point in time. While the
study claims to analyze performance on alleles for which
no or only limited data is available, these alleles are
never identified and only very limited information on
the results is given. Also, the performance on alleles for
which no data was available for training was poor. In
contrast, we have performed a detailed analysis of the
performance of predictors trained on one allele, and
their ability to accurately predict other alleles.
There have been several papers defining supertypes
using a number of different approaches [32,33]. Gener-
ally A*02 alleles and A*24 alleles are not clustered in
the same supertype. Our generalizability work was how-
ever able to make reasonable predictions for A*2402
(the only allele in our study of this supertype), using a
predictor trained on allele A*0201.
Conclusions
Until the creation of IEDB, the available peptide
sequence datasets were small and spread over many sepa-
rate efforts. In addition the datasets consisted predomi-
nantly of binding sequences, so that most prediction
models based on these data used random non-binding
Figure 3 Performance Comparison on Dataset F. The performance of the three prediction models, trained on Dataset F of A*0201 and tested
on Dataset F of all alleles (AUCs). NetMHC was not included in this analysis as the predictor is only available online and therefore could not be
trained by the authors.
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data for training purposes. Through the IEDB database a
sufficiently large number of experimentally verified non-
binders have become available for learning for the first
time. Therefore, the prediction models evaluated here
could not only be tested on a substantially larger number
of binders, but in addition experimentally verified non-
binders could be included in the training datasets and
alleles that have previously not been analyzed due to
insufficient dataset sizes could be included in the study.
As expected, Dataset S, which consisted only of pep-
tides for which a quantitative laboratory result was avail-
able in IEDB and which were either strong binders or
clear non-binders, performed better than Dataset F. As
the binding affinity at which a binder becomes a non-
binder has a threshold of 500 nM in IEDB, removing all
peptides from the dataset which we described as so-
called intermediate binders (50 nM to 1000 nM)
improved the performance of the methods (results not
shown), as did using a subset of data containing only
the very strongest binders and clearest non-binders. Due
to the error involved in experimental binding affinity
analysis [34], we suggest using a cutoff of 500 nM may
incorrectly categorize a weak binder as a non-binder or
vice versa. Perhaps adding a category containing such
intermediate binders, in addition to the already existing
categories binder and non-binder, would be a useful
addition to IEDB.
The excellent performance of NetMHC, on Dataset S in
particular where it performs with an AUC of 1 for many
alleles, may be in part due to the fact that this method
could not be trained for the purposes of this study as
NetMHC was only accessible via a web interface. It
should also be noted that some of the data used to train
NetMHC was probably identical to that extracted from
IEDB for this study. This conjecture is also supported by
the prediction results of the methods on the independent,
novel dataset, which showed no statistically significant
results between the methods (Table 4).
Peters et al. [16] performed an extensive analysis in
which they trained and tested their own in-house meth-
ods, but external methods were not reimplemented by
the authors. Instead, the available web interfaces for
external methods were used with the default settings. In
contrast to this, we reimplemented the external methods
YKW and SVMHC to allow for both training and testing.
The analysis of the reproducibility of the results of the
examined prediction models and their dependence on
the size of the available dataset (robustness) showed that
all methods require a sufficient number of data points
for reproducible results (Figure 2). Overall, most alleles
appear to require a minimum of 200 binders and 200
non-binders in Dataset F before the AUCs stabilize at or
close to their maximum level. We suggest that perform-
ing the analysis on alleles with too few data points
(which is still unfortunately the case with many HLA*B
alleles) can lead to unreliable results.
The analysis of the methods’ generalizability showed
that the prediction capabilities are good to marginal for
some alleles, implying that cross-allele prediction is fea-
sible in some cases. In other cases, the AUCs were very
low. Having trained with A*0201 and then tested for
generalizability on HLA-A and HLA-B alleles in Dataset
F, a possible reason for certain alleles to give rise to
such low AUCs may be that a particular subset of bin-
ders that bind well to A*0201 may be very clear non-
binders for the alleles in question. Conversely, clear
non-binders for A*0201 may be binders for the other
alleles leading to low AUCs.
In contrast to the former study [14], which included
only binding sequences (as sufficient numbers of experi-
mentally verified non-binding sequences were not avail-
able at that time) in testing generalizability, we observed
a much improved level of cross-allele prediction with
these newer datasets.
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